Table 2.

Surface under the cumulative ranking curve (SUCRA) values for all endpoints

SUCRA	Hospitalization for HF or CV death	All-cause mortality	CV mortality	Hospitalization for HF	Worsening RF	Worsening RF or CV death
Canagliflozin	0.708	0.691	0.726	0.752	0.565	0.412
Dapagliflozin	0.432	0.611	0.608	0.337	0.442	n.a.
Empagliflozin	0.425	0.386	0.503	0.347	0.672	0.439
Ertugliflozin	0.243	n.a.	n.a.	0.473	n.a.	n.a.
Licogliflozin	n.a.	0.559	0.347	n.a.	n.a.	n.a.
Placebo	0.041	0.192	0.251	0.020	0.082	0.403
Sitagliptin	0.809	0.558	0.550	0.819	0.739	0.671
Sotagliflozin	0.842	0.504	0.515	0.751	n.a.	n.a.

SUCRA is a transformation of the mean rank that accounts both for the location and the variance of all relative treatment effects. The larger the SUCRA value, the better the rank of the treatment [20]

CV cardiovascular, HF heart failure, n.a. not available, RF renal function